Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 566 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Open Surgery Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

IS-001 Injection Phase-1 Safety, Tolerance and Pharmacokinetics

NCT03006237
View directory record Official record
Conditions
Hysterectomy, Surgery
Interventions
IS-001, da Vinci® Si/Xi Surgical System
Drug · Device
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 30, 2026, 7:06 AM EDT
Terminated Phase 2 Interventional Results available

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

NCT03968419
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Canakinumab, Pembrolizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
La Jolla, California • Kansas City, Kansas • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 30, 2026, 7:06 AM EDT
Completed Phase 1 Interventional

SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery

NCT06300411
View directory record Official record
Conditions
Breast Cancer
Interventions
SRG-514
Drug
Lead sponsor
SURGE Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Savannah, Georgia • Indianapolis, Indiana • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 30, 2026, 7:06 AM EDT
Enrolling by invitation No phase listed Observational

5-Year Postoperative Outcomes of Patients Who Completed the CREST Study

NCT07480343
View directory record Official record
Conditions
Open-angle Glaucoma (OAG)
Interventions
CycloPen Micro-Interventional Cyclodialysis System, CycloPen Micro-Interventional Cyclodialysis System Post Cataract
Procedure
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 30, 2026, 7:06 AM EDT
Recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

NCT07499674
View directory record Official record
Conditions
Lung Cancer, Lung Metastases
Interventions
Abenacianine, Near Infrared (NIR) Imaging
Drug · Other
Lead sponsor
Vergent Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Duarte, California • Newport Beach, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 7:06 AM EDT
Completed Phase 1 Interventional

Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery

NCT02726438
View directory record Official record
Conditions
Bone Diseases, Infectious
Interventions
Debio 1450
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
La Mesa, California • Butte, Montana
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 30, 2026, 7:06 AM EDT
Withdrawn Not applicable Interventional

Microlyte in Prevention of SSI After Open Ventral Hernia Repair

NCT05093894
View directory record Official record
Conditions
Ventral Hernia
Interventions
Group 1
Device
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Asheville, North Carolina • Charlotte, North Carolina • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 30, 2026, 7:06 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

NCT00025181
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, ipilimumab, tyrosinase peptide, adjuvant therapy
Biological · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 30, 2026, 7:06 AM EDT
Completed No phase listed Observational Results available

Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort

NCT01836042
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Glaukos Corporation
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Beverly Hills, California • Petaluma, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 30, 2026, 7:06 AM EDT
Terminated Phase 4 Interventional

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

NCT06407973
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
45 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Petaluma, California • Maryville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 30, 2026, 7:06 AM EDT
Active, not recruiting Not applicable Interventional

Acupuncture for the Management of Postoperative Pain in Patients With Pancreatic or Colorectal Cancer Undergoing Surgery

NCT04560712
View directory record Official record
Conditions
Resectable Colorectal Carcinoma, Resectable Digestive System Carcinoma, Resectable Pancreatic Carcinoma
Interventions
Acupuncture Therapy, Best Practice, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 30, 2026, 7:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hyperglycemia in Neurosurgery

NCT05236751
View directory record Official record
Conditions
Hyperglycemia, Postoperative Infection
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 30, 2026, 7:06 AM EDT
Completed Phase 1 Interventional

Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery

NCT02603965
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Copper Cu 64 TP3805, Positron Emission Tomography, Computed Tomography, Radical Prostatectomy, Laboratory Biomarker Analysis
Radiation · Procedure · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
21 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 30, 2026, 7:06 AM EDT
Terminated Not applicable Interventional

Open Versus Endovascular Repair of Popliteal Artery Aneurysm Trial

NCT01817660
View directory record Official record
Conditions
Popliteal Artery Aneurysm
Interventions
Open repair of popliteal artery, Endovascular repair of popliteal artery
Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
35 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 30, 2026, 7:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery

NCT00575380
View directory record Official record
Conditions
Bacterial Infections, Eye Infections, Cataract Extraction
Interventions
AzaSite Eye Drops, Vigamox Eye Drops
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
21 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Mission Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Oct 30, 2026, 7:06 AM EDT
Completed Phase 1 Interventional Results available

A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas

NCT00711191
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
monoclonal antibody, chemotherapy
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 30, 2026, 7:06 AM EDT
Not listed Phase 2 Interventional

Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy

NCT00003856
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
temoporfin
Drug
Lead sponsor
Quintiles, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
7
States / cities
Little Rock, Arkansas • Tampa, Florida • Evanston, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 30, 2026, 7:06 AM EDT
Completed Phase 2 Interventional

Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery

NCT00769470
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, docetaxel, lapatinib ditosylate
Biological · Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
15
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 30, 2026, 7:06 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study Of Surgical Repair Of Discontinuous Branching Pulmonary Arteries

NCT07785661
View directory record Official record
Conditions
Absent Pulmonary Artery
Interventions
Acellular Tissue Engineered Vessel (ATEV) Conduit
Biological
Lead sponsor
Joseph Dearani
Other
Eligibility
6 Months to 2 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 30, 2026, 7:06 AM EDT
Completed Not applicable Interventional

Transluminal Flexible Endoscopic Procedure in Foregut and Urologic Surgery

NCT00484783
View directory record Official record
Conditions
Gastric Foreign Body, Nos, Disorder of Abdomen (Disorder), Foreign Body in Esophagus, Prostatic Diseases, Disease of Small Intestine
Interventions
Natural Orifice Transluminal Endoscopic Surgery (NOTES), Natural Orifice Translumenal Endoscopic Surgery (NOTES)
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 30, 2026, 7:06 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Combined Phacoemulsification With iStent Inject W Versus Hydrus for Mild to Moderate Open Angle Glaucoma

NCT05583591
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Combined cataract surgery with Hydrus microstent, Combined cataract surgery with iStent Inject W
Device
Lead sponsor
Diablo Eye Associates
Industry
Eligibility
60 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 30, 2026, 7:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy Comparison of Two Preoperative Skin Antisepsis Preparations in Colorectal Surgery

NCT01233050
View directory record Official record
Conditions
Colorectal Surgery
Interventions
2% Chlorhexidine Gluconate/70% Isopropyl Alcohol, Iodine Povacrylex/74% Isopropyl Alcohol
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 30, 2026, 7:06 AM EDT
Terminated Phase 2 Interventional Results available

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

NCT03912818
View directory record Official record
Conditions
Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Giant Cells, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation, Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Nested Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
Interventions
Carboplatin, Cisplatin, Cystectomy, Doxorubicin, Durvalumab, Gemcitabine, Methotrexate, Vinblastine
Drug · Procedure · Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 30, 2026, 7:06 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

NCT04003623
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, FGFR Mutations, FGFR Translocations
Interventions
Pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Fountain Valley, California • Ocala, Florida • Honolulu, Hawaii + 8 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 30, 2026, 7:06 AM EDT